BioAtla, Inc.
BCABNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $2.16M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.41$23.65
- Volume (live)
- -
- Avg. volume (3M)
- 17.12K
BioAtla (BCAB) Stock Price & Financial Analysis
BioAtla Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.29 - $1.30 |
|---|---|
| 52-Week High | $23.65 |
| 52-Week Low | $0.41 |
| Open | $1.30 |
| Volume (last close) | 3.30K |
| Average Volume (3M) | 17.12K |
| Revenue (TTM) | 8.50M |
|---|---|
| Net Income (TTM) | -31.45M |
| Free Cash Flow (TTM) | -23.48M |
| EPS (TTM) | −$22.73 |
| Profit Margin | -370.05% |
| Operating Margin | -377.94% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 2.16M |
|---|---|
| Shares Outstanding | 1.66M |
| Price to Sales (P/S) | 0.25 |
| Price to Book (P/B) | -0.06 |
| EV/EBITDA | -0.20 |
| 50-Day MA | $2.09 |
|---|---|
| 200-Day MA | $5.63 |
| 1-Year Change | +76.56% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
BioAtla at a Glance
As of the Oct 15, 2026 close, BioAtla (BCAB) has a market capitalization of $2.16M. The stock trades at 0.3× sales. Over the trailing twelve months it lost $31.45M on revenue of $8.50M and burned $23.48M of free cash flow. Revenue fell 22.7% year over year.
As of its latest reported balance sheet, it holds $1.54M in cash and securities against $5.86M of debt, a net debt position of $4.32M.
BioAtla does not currently pay a dividend.
The share price is up 76.6% over the past year. At $1.30 (the Oct 15, 2026 close) it sits near the bottom of its 52-week range of $0.41 to $23.64, below its 200-day moving average of $5.63.
Frequently Asked Questions About BioAtla
What is the current stock price for BCAB?
As of the Oct 15, 2026 close, BCAB stock trades at $1.30. The 52-week range is $0.41–$23.65, with a day range of $1.29–$1.30.
What is the P/E ratio for BCAB?
The P/E ratio (Price-to-Earnings) for BCAB is shown in the Key Statistics section. This valuation metric helps compare BioAtla, Inc. to industry peers.
Does BCAB pay dividends?
BioAtla does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BCAB?
Analyst ratings and recommendations for BCAB are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of BCAB?
As of the Oct 15, 2026 close, BioAtla's market capitalization is $2.2M, classifying it as a micro-cap company. BioAtla operates in the Healthcare sector within the Biotechnology industry.